Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UHEOR
ADC Name
HS-20089
Synonyms
HS20089; HS 20089
   Click to Show/Hide
Organization
Shanghai Hansoh Biomedical Co. Ltd.
Drug Status
Phase 2
Indication
In total 5 Indication(s)
Endometrial cancer
Phase 2
Fallopian tube cancer
Phase 2
Ovarian cancer
Phase 2
Primary peritoneal cancer
Phase 2
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
Drug-to-Antibody Ratio
6
Antibody Name
Undisclosed
Antigen Name
V-set domain-containing T-cell activation inhibitor 1 (VTCN1)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05263479
Phase 1
A phase 1, open-label, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HS-20089 in patients with advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05263479  Clinical Status Phase 1
Clinical Description A phase 1, open-label, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HS-20089 in patients with advanced solid tumors.
References
Ref 1 A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20089 in Patients With Advanced Solid Tumors, NCT05263479

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.